A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder.
Mototsugu ItoMark WalzerMary Beth BlauwetAnna SpenceNakyo HeoDebra KelshPaul BlahunkaJay ErdmanMohamad Nour AlsharifGerard J MarekPublished in: Journal of psychopharmacology (Oxford, England) (2023)
Clinicaltrials.gov identifier: NCT04447287.